

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934**

**For the Month of: October 2019**

**Commission File Number: 001-37847**

**MOTIF BIO PLC**

(Exact name of registrant as specified in its charter)

**125 Park Avenue**

**25<sup>th</sup> Floor**

**New York, New York 10017**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_

---

---

**MOTIF BIO PLC  
FORM 6-K**

**CHANGE OF ADVISER**

On October 3, 2019, Motif Bio plc (the “Company”) issued a regulatory news service announcement stating that it appointed SP Angel Corporate Finance LLP as its nominated adviser and sole corporate broker with immediate effect. A copy of the regulatory news service announcement is attached herein as Exhibit 99.1.

The information contained in this report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-222614 and 333-222042), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

**Exhibits**

[Exhibit 99.1](#) Regulatory news service announcement issued on October 3, 2019, entitled “Change of Adviser.”

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MOTIF BIO PLC

By: /s/ Graham Lumsden  
Name: Graham Lumsden  
Title: Chief Executive Officer

Date: October 3, 2019

---



3 October 2019

**Motif Bio plc**  
 (“Motif Bio”, or “the Company”)

**Change of Adviser**

Motif Bio plc (AIM/NASDAQ: MTFB) is pleased to announce the appointment of SP Angel Corporate Finance LLP as nominated adviser and sole corporate broker with immediate effect.

**AIM Rule 17 Disclosure**

In accordance with AIM Rule 17 and Schedule Two (g) sub-paragraph (v) of the AIM Rules for Companies (the “AIM Rules”), the Company has been informed by Dr. Mary Lake Polan, Non-executive Director, that NovaTract Surgical, Inc. a US company of which Dr. Polan was a Director, entered into liquidation in 2015.

**Update to disclosures required by Schedule 2(g) of the AIM Rules**

In addition to the directorships disclosed in the Company's admission document dated 27 March 2015, directors of the Company were, or had been in the past five years, at that time, directors of the following companies:

<b>Director</b>	<b>Current Directorships</b>	<b>Directorships held within the past 5 years</b>
Jonathan Gold	Subotnick House	N/A

In addition to the past directorships disclosed in the announcement of the appointment of Andrew Powell on 26 April 2019, Andrew Powell had, at that time, been in the past five years a director of the following companies:

Intermune UK Limited  
 Intermune UK & I Limited  
 Intermune Holdings Limited  
 Intermune Bristol Limited  
 Medivation Europe Limited

The person responsible for the release of this announcement on behalf of Motif Bio plc is Jonathan Gold, Interim Chief Financial Officer.

*This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.*



**For further information, please contact:**

**Motif Bio plc**

Graham Lumsden (Chief Executive Officer)

ir@motifbio.com

**SP Angel Corporate Finance LLP (NOMAD & BROKER)**

David Hignell/Caroline Rowe (Corporate Finance)  
Vadim Alexandre/Abigail Wayne (Sales & Broking)

+44 (0)20 3470 0470

**Walbrook PR Ltd. (UK FINANCIAL PR & IR)**

Paul McManus/Lianne Cawthorne

+44 (0)20 7933 8780  
motifbio@walbrookpri.com

**MC Services AG (EUROPEAN IR)**

Raimund Gabriel

+49 (0)89 210 2280  
raimund.gabriel@mc-services.eu

**Forward-Looking Statements**

This press release contains forward-looking statements. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) Motif Bio’s ability to obtain shareholder approval in connection with the Proposed Restructuring, (ii) Motif Bio’s ability to execute the Proposed Capital Raise and Proposed Restructuring (iii) the timing, progress and the results of clinical trials for Motif Bio’s product candidates, (iv) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio’s product candidates, (v) Motif Bio’s ability to successfully commercialise its product candidates, (vi) Motif Bio’s ability to effectively market any product candidates that receive regulatory approval, (vii) Motif Bio’s commercialisation, marketing and manufacturing capabilities and strategy, (viii) Motif Bio’s expectation regarding the safety and efficacy of its product candidates, (ix) the potential clinical utility and benefits of Motif Bio’s product candidates, (x) Motif Bio’s ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, (xi) Motif Bio’s estimates regarding the potential market opportunity for its product candidates, (xii) Motif Bio’s ability to raise additional capital to sustain its operations and pursue its strategy and (xiii) the factors discussed in the section entitled “Risk Factors” in Motif Bio’s Annual Report on Form 20-F filed with the SEC on April 15, 2019, which is available on the SEC’s web site, [www.sec.gov](http://www.sec.gov). Additionally, there can be no assurance that Motif Bio will regain compliance with Nasdaq rules or maintain its ADS listing on Nasdaq. Motif Bio undertakes no obligation to update or revise any forward-looking statements

---